Bufalin suppresses hepatocellular carcinoma invasion and metastasis by targeting HIF-1α via the PI3K/AKT/mTOR pathway

Oncotarget

Volumn 7, Issue 15, 2016, Pages 20193-20208

  Wang, Haiyong ^a,b   Zhang, Chenyue ^a,c   Xu, Litao ^a,c   Zang, Kun ^a,c   Ning, Zhouyu ^a,c   Jiang, Feng ^d   Chi, Huiying ^e   Zhu, Xiaoyan ^a,c   Meng, Zhiqiang ^a,c  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b SHANDONG CANCER HOSPITAL AND INSTITUTE   (China)

^c FUDAN UNIVERSITY   (China)

^d Zhucheng Hospital of TCM   (China)

^e SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Bufalin; Hepatocellular carcinoma; HIF 1 ; Metastasis; PI3K AKT mTOR

Indexed keywords

BUFALIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; NERVE CELL ADHESION MOLECULE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; TRANSCRIPTION FACTOR SNAIL; TRANSFORMING GROWTH FACTOR BETA1; UVOMORULIN; VASCULOTROPIN; VIMENTIN; AKT1 PROTEIN, HUMAN; ANTINEOPLASTIC AGENT; BUFADIENOLIDE DERIVATIVE; HIF1A PROTEIN, HUMAN; MTOR PROTEIN, HUMAN; TARGET OF RAPAMYCIN KINASE; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG MECHANISM; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; LIVER METASTASIS; LUNG METASTASIS; METASTASIS INHIBITION; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TUMOR INVASION; ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG SCREENING; GENE EXPRESSION REGULATION; LIVER TUMOR; METABOLISM; METASTASIS; NUDE MOUSE; PATHOLOGY; SECONDARY; TUMOR CELL CULTURE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOMARKERS, TUMOR; BUFANOLIDES; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; EPITHELIAL-MESENCHYMAL TRANSITION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; LIVER NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84964723040     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7935     Document Type: Article

References (49)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61:69-90.
2. Gao JJ, Song PP, Tamura S, Hasegawa K, Sugawara Y, Kokudo N, Uchida K, Orii R, Qi FH, Dong JH, Tang W. Standardization of perioperative management on hepatobiliary-pancreatic surgery. Drug Discov Ther. 2012; 6:108-111.
3. Belghiti J, Fuks D. Liver resection and transplantation in hepatocellular carcinoma. Liver Cancer. 2012; 1:71-82.
4. Cheah YL, Chow P. Liver transplantation for hepatocellular carcinoma: an appraisal of current controversies. Liver Cancer. 2012; 1:183-189.
5. Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol. 2005; 43:584-589.
6. Qi F, Li A, Inagaki Y, Kokudo N, Tamura S, Nakata M, Tang W: Antitumor activity of extracts and compounds from the skin of the toad Bufo bufo gargarizans Cantor. Int Immunopharmacol 2011, 11:342-349.
7. Hong SH, Kim GY, Chang YC, Moon SK, Kim WJ, Choi YH. Bufalin prevents the migration and invasion of T24 bladder carcinoma cells through the inactivation of matrix metalloproteinases and modulation of tight junctions. Int J Oncol. 2013; 42:277-286.
8. Lee JM, Dedhar S, Kalluri R, Thompson EW. The epithelialmesenchymal transition: new insights in signaling, development, and disease. J Cell Biol. 2006; 172:973-981.
9. Wang Y, Wen M, Kwon Y, Xu Y, Liu Y, Zhang P, He X, Wang Q, Huang Y, Jen KY, LaBarge MA, You L, Kogan SC, et al. CUL4A induces epithelial-mesenchymal transition and promotes cancer metastasis by regulating ZEB1 expression. Cancer Res. 2014; 74:520-531.
10. Franco-Chuaire ML, Magda Carolina SC, Chuaire-Noack L. Epithelial-mesenchymal transition (EMT): principles and clinical impact in cancer therapy. Invest Clin. 2013; 54:186-205.
11. Yang MH, Chen CL, Chau GY, Chiou SH, Su CW, Chou TY, Peng WL, Wu JC. Comprehensive analysis of the independent effect of twist and snail in promoting metastasis of hepatocellular carcinoma. Hepatology. 2009; 50:1464-1474.
12. Zhou Z, Zhao C, Wang L, Cao X, Li J, Huang R, Lao Q, Yu H, Li Y, Du H, Qu L, Shou C. A VEGFR1 antagonistic peptide inhibits tumor growth and metastasis through VEGFR1-PI3K-AKT signaling pathway inhibition. Am J Cancer Res. 2015;5:3149-3161
13. Myung SJ, Yoon JH. Hypoxia in hepatocellular carcinoma. The Korean journal of hepatology. 2007; 1:9-19.
14. Luo D, Wang Z, Wu J, Jiang C, Wu J. The role of hypoxia inducible factor-1 in hepatocellular carcinoma. Biomed Res Int. 2014; 2014:409272.
15. Xiao H, Tong R, Ding C, Lv Z, Du C, Peng C, Cheng S, Xie H, Zhou L, Wu J, Zheng S. Y-H2AX promotes hepatocellular carcinoma angiogenesis via EGFR/HIF-1a/VEGF pathways under hypoxic condition. Oncotarget. 2015; 6:2180-2192. doi: 10.18632/oncotarget.2942.
16. Rigiracciolo DC, Scarpelli A, Lappano R, Pisano A, Santolla MF, De Marco P, Cirillo F, Cappello AR, Dolce V, Belfiore A, Maggiolini M, De Francesco EM. Copper activates HIF-1α/GPER/VEGF signalling in cancer cells. Oncotarget. 2015; 6:34158-34177. doi: 10.18632/oncotarget.5779.
17. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH, Semenza GL. Hypoxiainducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressor-null renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Research. 2006; 5:2725-2731.
18. Yang MH, Wu MZ, Chiou SH, Chen PM, Chang SY, Liu CJ, Teng SC, Wu KJ. Direct regulation of TWIST by HIF-1alpha promotes metastasis. Nature Cell Biology. 2008; 3:295-305.
19. Zhang L, Huang G, Li X, Zhang Y, Jiang Y, Shen J, Liu J, Wang Q, Zhu J, Feng X, Dong J, Qian C. Hypoxia induces epithelial mesenchymal transition via activation of SNAI1 by hypoxia inducible factor-1α in hepatocellular carcinoma. BMC Cancer. 2013; 13:108.
20. Liu Y, Zhang JB, Qin Y, Wang W, Wei L, Teng Y, Guo L, Zhang B, Lin Z, Liu J, Ren ZG, Ye QH, Xie Y. PROX1 promotes hepatocellular carcinoma metastasis by way of up-regulating hypoxia inducible factor 1a expression and protein stability. Hepatology. 2013; 2:692-705.
21. Guo R, Meng Q, Guo H, Xiao L, Yang X, Cui Y, Huang Y. TGFβ-2 induces epithelial-mesenchymal transition in cultured human lens epithelial cells through activation of thePI3K/Akt/mTOR signaling pathway. Mol Med Rep. 2016; 13:1105-1110.
22. Xiang ZL. Zeng ZC, Fan J, Tang ZY, Zeng HY, Gao DM. Gene expression profiling of fixed tissues identified hypoxia-inducible factor-1α, VEGF, and matrix metalloproteinase-2 as biomarkers of lymph node metastasis in hepatocellular carcinoma. Clin Cancer Res. 2011; 17:5463-5472.
23. Jiang H, Zhu YS, Xu H, Sun Y, Li QF. Inflammatory stimulation and hypoxia cooperatively activate HIF-1(alpha) in bronchial epithelial cells: involvement of PI3K and NF-(kappa)B. Am J Physiol Lung Cell Mol Physiol. 2010; 298:L660-L669.
24. Dai R, Chen R, Li H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. Int J Oncol. 2009; 34:1749-1757.
25. Qiao M, Sheng S, Pardee AB. Metastasis and AKT activation. Cell Cycle. 2008; 7:2991-2996.
26. Zhao L, Liu S, Che X, Hou K, Ma Y, Li C, Wen T, Fan Y, Hu X, Liu Y, Qu X. Bufalin inhibits TGFβ-induced epithelial-to-mesenchymal transition and migration in human lung cancer A549 cells by downregulating TGFβ-receptors. 2015; 36:645-652.
27. Zhang ZJ, Yang YK, Wu WZ. Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice. J Transl Med. 2014; 12:57.
28. Qiu DZ, Zhang ZJ, Wu WZ, Yang YK. Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells. BMC Complement Altern Med. 2013; 13:185.
29. Thiery JP. Epithelial-mesenchymal transitions in tumor progression. Nat Rev Cancer. 2002; 2:442-454.
30. Amin R, Mishra L. Liver stem cells and tgf-Beta in hepatic carcinogenesis. Gastrointest Cancer Res. 2008; 2:S27-30.
31. Roberts AB, Wakefield LM. The two faces of transforming growth factor beta in carcinogenesis. Proc Natl Acad Sci USA. 2003; 100:8621-8623.
32. Abou-Shady M, Baer HU, Friess H, Berberat P, Zimmermann A, Graber H, Gold LI, Korc M, Büchler MW. Transforming growth factor betas and their signaling receptors in human hepatocellular carcinoma. Am J Surg. 1999; 177:209-215.
33. Mishra L, Shetty K, Tang Y, Stuart A, Byers SW. The role of TGF-beta and Wnt signaling in gastrointestinal stem cells and cancer. Oncogene. 2005; 24:5775-5789.
34. Xu J, Lamouille S, Derynck R. TGF beta-induced epithelial to mesenchymal transition. Cell Res. 2009; 19:156-172.
35. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003; 10:721-732.
36. Hao J, Song X, Song B, Liu Y, Wei L, Wang X, Yu J. Effects of lentivirus-mediated HIF-1alpha knockdown on hypoxia-related cisplatin resistance and their dependence on p53 status in fibrosarcoma cells. Cancer Gene Ther. 2008; 7:449-455.
37. Samulitis BK, Landowski TH, Dorr RT. Inhibition of protein synthesis by imexon reduces HIF-1alpha expression in normoxic and hypoxic pancreatic cancer cells. Invest New Drugs. 2009; 1:89-98.
38. Burrows N, Resch J, Cowen RL, von Wasielewski R, Hoang-Vu C, West CM, Williams KJ, Brabant G. Expression of hypoxia-inducible factor 1 alpha in thyroid carcinomas. Endocr Relat Cancer. 2010; 1:61-72.
39. Seeber LM, Horrée N, van der Groep P, van der Wall E, Verheijen RH, van Diest PJ. Necrosis related HIF-1alpha expression predicts prognosis in patients with endometrioid endometrial carcinoma. BMC Cancer. 2010; 10:307.
40. Vumbaca F, Phoenix KN, Rodriguez-Pinto D, Han DK, Claffey KP. Double-stranded RNA-binding protein regulates vascular endothelial growth factor mRNA stability, translation, and breast cancer angiogenesis. Mol Cell Biol. 2008; 2:772-783.
41. Zheng SS, Chen XH, Yin X, Zhang BH. Prognostic significance of HIF-1α expression in hepatocellular carcinoma: a meta analysis. PLoS ONE. 2013; 8:e65753.
42. Cao S, Yang S, Wu C, Wang Y, Jiang J, Lu Z. Protein expression of hypoxia inducible factor-1 alpha and hepatocellular carcinoma: a systematic review with meta-analysis. Clinics and Research in Hepatology and Gastroenterology. 2014; 38:598-603.
43. Lin J, Carducci MA. HIF-1alpha inhibition as a novel mechanism of cardiac glycosides in cancer therapeutics. Expert Opin Investig Drugs. 2009; 18:241-243.
44. Zhang H, Qian DZ, Tan YS, Lee K, Gao P, Ren YR, Rey S, Hammers H, Chang D, Pili R, Dang CV, Liu JO, Semenza GL. Digoxin and other cardiac glycosides inhibit HIF-1alpha synthesis and block tumor growth. Proc Natl Acad Sci USA. 2008; 105:19579-19586.
45. Tommasi S, Pinto R, Pilato B, Paradiso A. Molecular pathways and related target therapies in liver carcinoma. Curr Pharm Des. 2007; 13:3279-3287.
46. Sun CH, Chang YH, Pan CC. Activation of the PI3K/Akt/mTOR pathway correlates with tumour progression and reduced survival in patients with urothelial carcinoma of the urinary bladder. Histopathology. 2011; 58:1054-1063.
47. Agani F, Jiang BH. Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets. 2013; 13:245-251.
48. Aksamitiene E, Kiyatkin A, Kholodenko BN. Crosstalk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans. 2012; 40:139-146.
49. Wang Y, Lonard DM, Yu Y, Chow DC, Palzkill TG, Wang J, Qi R, Matzuk AJ, Song X, Madoux F, Hodder P, Chase P, Griffin PR, et al. Bufalin is a potent small-molecule inhibitor of the steroid receptor coactivators SRC-3 and SRC-1. Cancer Res. 2014; 74:1506-1517.